Celcuity Inc. (CELC)
| Market Cap | 6.34B +1,412.3% |
| Revenue (ttm) | n/a |
| Net Income | -177.04M |
| EPS | -3.79 |
| Shares Out | 48.34M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 799,725 |
| Open | 130.71 |
| Previous Close | 130.71 |
| Day's Range | 129.23 - 133.40 |
| 52-Week Range | 9.51 - 151.02 |
| Beta | 0.09 |
| Analysts | Strong Buy |
| Price Target | 131.56 (+0.38%) |
| Earnings Date | May 14, 2026 |
About CELC
Celcuity Inc., a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company’s lead drug candidate includes Gedatolisib, which selectively targets various Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2 to treat patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) or HR+/HER2-, advanced or metastatic... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 9 analysts, the average rating for CELC stock is "Strong Buy." The 12-month stock price target is $131.56, which is an increase of 0.38% from the latest price.
News
Celcuity Schedules Release of First Quarter 2026 Financial Results and Webcast/Conference Call
MINNEAPOLIS, May 07, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it will...
Celcuity price target raised to $189 from $141 at Craig-Hallum
Craig-Hallum analyst Chase Knickerbocker raised the firm’s price target on Celcuity (CELC) to $189 from $141 and keeps a Buy rating on the shares following the company’s announcement of statistically
Celcuity price target raised to $165 from $135 at Guggenheim
Guggenheim analyst Brad Canino raised the firm’s price target on Celcuity (CELC) to $165 from $135 and keeps a Buy rating on the shares. With the positive VIKTORIA-1 Phase 3
Celcuity price target raised to $157 from $122 at Needham
Needham raised the firm’s price target on Celcuity (CELC) to $157 from $122 and keeps a Buy rating on the shares. The firm is citing the company announcements that geda
Celcuity price target raised to $150 from $125 at Stifel
Stifel analyst Stephen Willey raised the firm’s price target on Celcuity (CELC) to $150 from $125 and keeps a Buy rating on the shares. The firm views the “statistically significant
Celcuity upgraded to Buy from Neutral at H.C. Wainwright
H.C. Wainwright upgraded Celcuity (CELC) to Buy from Neutral with a price target of $165, up from $94. The company announced positive results from the PIK3CA mutant advanced breast cancer
Celcuity price target raised to $160 from $150 at Citizens
Citizens raised the firm’s price target on Celcuity (CELC) to $160 from $150 and keeps an Outperform rating on the shares. Celcuity’s second Phase 3 success suggests gedatolisib could expand
Celcuity’s Phase 3 VIKTORIA-1 trial achieves primary endpoint
Celcuity (CELC) announced positive topline results from the PIK3CA mutant cohort of the Phase 3 VIKTORIA-1 clinical trial evaluating gedatolisib plus fulvestrant with or without palbociclib in patient...
Celcuity's Phase 3 VIKTORIA-1 Trial Achieves Primary Endpoint With Clinically Meaningful Improvement in Progression-Free Survival in PIK3CA Mutant Cohort
Detailed data for the gedatolisib triplet and doublet regimens will be presented at a late-breaking abstract oral session at the 2026 ASCO Annual Meeting Detailed data for the gedatolisib triplet and ...
Celcuity trading halted, news pending
16:00 EDT Celcuity (CELC) trading halted, news pending
Celcuity initiated with an Outperform at Citizens
Citizens initiated coverage of Celcuity (CELC) with an Outperform rating and $150 price target The company is focused on targeted therapies in oncology and its gedatolisib regimen “may provide an
Celcuity price target raised to $141 from $108 at Craig-Hallum
Craig-Hallum raised the firm’s price target on Celcuity (CELC) to $141 from $108 and keeps a Buy rating on the shares following the Q4 update, which was largely in line
Celcuity price target raised to $125 from $115 at Stifel
Stifel analyst Stephen Willey raised the firm’s price target on Celcuity (CELC) to $125 from $115 and keeps a Buy rating on the shares. The firm’s updated target price primarily
Celcuity Earnings Call Transcript: Q4 2025
Achieved key milestones in 2025, including FDA priority review for gedatolisib and strong pivotal trial results. Net loss increased due to R&D and commercial investments, but cash reserves are expected to fund operations through 2027. Positive market feedback and a large addressable market support a strong outlook.
Celcuity reports Q4 EPS (73c), consensus ($1.01)
Cash, cash equivalents and short-term investments were $441.5M at the end of fiscal year 2025 and are expected to finance our operations through 2027. “We expect this year to be
Celcuity Inc. Reports Release of Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
MINNEAPOLIS, March 25, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced financial ...
Celcuity Schedules Release of Fourth Quarter and Full Year 2025 Financial Results and Webcast/Conference Call
MINNEAPOLIS, March 18, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it wi...
Celcuity Transcript: Leerink Global Healthcare Conference 2026
Gedatolisib has shown unprecedented efficacy in second-line breast cancer, with strong early results in both wild-type and mutant populations. Commercial launch preparations are nearly complete, with a mid-July approval targeted, and international expansion is planned following key data readouts.
Celcuity price target raised to $122 from $95 at Needham
Needham raised the firm’s price target on Celcuity (CELC) to $122 from $95 and keeps a Buy rating on the shares.
Celcuity reports results from PIK3CA WT cohort of Phase 3 VIKTORIA-1 trial
Celcuity (CELC) announced publication of efficacy and safety results from the PIK3CA wild-type cohort of the Phase 3 VIKTORIA-1 clinical trial of gedatolisib, an investigational pan-PI3K/mTORC1/2 inhi...
Celcuity Announces Publication of Results from PIK3CA Wild-Type Cohort of Phase 3 VIKTORIA-1 Study of Gedatolisib Regimens in HR+/HER2- Advanced Breast Cancer in Journal of Clinical Oncology
MINNEAPOLIS, March 09, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced publicatio...
Celcuity Transcript: TD Cowen 46th Annual Health Care Conference
Three clinical trials are advancing for Gedatolisib, with key mutant data expected soon and strong confidence in regulatory timelines. Launch preparations are on track, targeting a large breast cancer market with a favorable safety profile and significant peak revenue potential.